CCRB Logo

Trial History Detail on 2013-01-14

CUHK_CCT00156

2008-02-15

Prospective

Not applicable

N/A

Nil

Nil

Miss Joyce Kung

3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon

27623134

joycekung@cuhk.edu.hk

Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong

Prof. Dennis SC Lam

3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon.

27623134

dennislam_cu_res@cuhk.edu.hk

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong

Intravitreal injection of Bevacizumab (Avastin®) as an adjunctive therapy of pterygium surgery to prevent recurrence: A pilot study

Intravitreal injection of Bevacizumab (Avastin®) as an adjunctive therapy of pterygium surgery to prevent recurrence: A pilot study

Not applicable

Hong Kong

Yes

2008-01-31

pterygium

Procedure

Intravitreal injection of Bevacizumab (Avastin®) after surgical excision of pterygium

one injection immediately after surgical excision of pterygium

There is no comparative treatment as this is a pilot study. We will observe the recurrence rate of pterygium being treated with adjunctive intravitreal Avastin injection and design a randomized controlled trial in the future.

Inclusion criteria: 1. Age 18 years or above 2. Eye with single-head primary or secondary pterygium 3. Patient able and willing to give informed consent to the pterygium surgery with intravitreal injections of bevacizumab

Exclusion criteria: 1. Single functional eye 2. Pregnant patients 3. Use of anticoagulants or antiplatelet therapy other than aspirin / NSAID within 14 days of surgery.

18

None set

Both Male and Female

Interventional

Non-randomized

Uncontrolled

Open label

Single group

2008-03-01

50 eyes

Complete

Recurrence of pterygium, up to 24 months post op

- Visual acuity (VA) - Intraocular pressure (IOP) - Corneal endothelial cell counts - Corneal astigmatism - Any complications from the injections

No

2013-01-14

ChiCTR-TRC-09000714

2010-05-04


Yes

Type Access Document Published On  
No documents yet.
  • Page 1 of 1.